238 related articles for article (PubMed ID: 35896082)
1. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.
Gutzmer R; Schulze HJ; Hauschild A; Leiter U; Meier F; Haferkamp S; Ulrich C; Wahl RU; Berking C; Herbst R; Häckl M; Schadendorf D
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1678-1685. PubMed ID: 33931910
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
8. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
14. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA; Pop OT; Ighilahriz M; Padioleau I; Rajabi F; Sharpe HJ; Poulalhon N; Dreno B; Khammari A; Delord M; Alberti A; Soufir N; Battistella M; Mourah S; Bouquet F; Savina A; Besse A; Mendez-Lopez M; Grange F; Monestier S; Mortier L; Meyer N; Dutriaux C; Robert C; Saiag P; Herms F; Lambert J; de Sauvage FJ; Dumaz N; Flatz L; Basset-Seguin N; Nikolaev SI
Clin Cancer Res; 2022 Apr; 28(7):1422-1432. PubMed ID: 35078858
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma.
Juzot C; Isvy-Joubert A; Khammari A; Knol AC; Nguyen JM; Dreno B
Eur J Dermatol; 2022 May; 32(3):401-407. PubMed ID: 36065537
[TBL] [Abstract][Full Text] [Related]
16. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
17. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Kaatz M; Mohr P; Livingstone E; Weichenthal M; Kreuter A; Pföhler C; Leiter U; Ulrich J; Utikal JS; Gutzmer R; Herbst R; Schadendorf D
Acta Derm Venereol; 2022 Apr; 102():adv00695. PubMed ID: 35199180
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]